Home Trials Current Trials

ASTN Current Trials

EXTEND-IA TNK: Extending the time for thrombolysis in emergency neurological deficits - intra-arterial with tenecteplase

E-mail Print PDF

Lead PI: Dr Bruce Campbell

Status: Recruiting / Site Selection

 No. of Patients Currently Recruited: 53                                No. of Patients Required:  tbc

Rapid reperfusion is the key to improved ischemic stroke outcomes. Tenecteplase may be safer and more effective than alteplase. The hypothesis of the EXTEND-IA TNK randomised trial is that intravenous tenecteplase will achieve reperfusion prior to cerebral angiography more frequently than intravenous alteplase in patients eligible for clot retrieval.

Trial URL:

Clinicaltrials.gov NCT02388061

 

Last Updated ( Wednesday, 06 July 2016 14:49 )
 

VERSE: Very Early Rehabilitation in Speech after Stroke

E-mail Print PDF

Lead PI: Associate Professor Erin Godecke

Status: Recruiting

No. of Patients Currently Recruited: 222                                No. of Patients Required:  246

This 3-arm randomised controlled trial (RCT) aims to determine whether a standardised, intensive aphasia therapy regimen (VERSE) is more effective and cost saving than intensive non-standardised usual care training (UC-Plus) and regular usual care (US) therapy provided at 12 weeks post stroke.

Trial URL:

ANZCTR No: ACTRN12613000776707

http://www.ncbi.nlm.nih.gov/pubmed/?term=2016+Jul%3B11(5)%3A586-92

 

Last Updated ( Wednesday, 10 January 2018 12:44 )
 

AFFINITY: Assessment of fluoxetine in stroke recovery trial

E-mail Print PDF

Lead PI:  Graeme J Hankey and Maree L. Hackett

Status: Recruiting

No. of Patients Currently Recruited: 389                                No. of Patients Required:  1600

An Australian-lead investigator initiated, multi-centre, prospective, randomized, parallel group, double blind placebo-controlled trial to establish the effect(s) of routine administration of fluoxetine (20mg once daily) for 6 months in patients with recent stroke on functional outcome at 6 months and one year.

Setting: Stroke Units in Australia, New Zealand and Vietnam

Primary Aim: Does treatment with fluoxetine, 20 mg once daily, started 2-15 days after stroke onset and continued for 180 days, improve functional outcome at 180 days after randomisation?

Trial URL:

ANZCTR No: ACTRN12611000774921

https://www.affinitytrial.org

http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-0864-1

Last Updated ( Wednesday, 10 January 2018 12:43 )
 

COMPARE: Participant Information for People With Aphasia Constraint Induced or Multi-Modal aphasia rehabilitation: A Randomised Controlled Trial (RCT) for stroke related chronic aphasia

E-mail Print PDF

Lead PI: Associate Professor Miranda Rose

Status: Recruiting

No. of Patients Currently Recruited: 26                                No. of Patients Required:  216

COMPARE is a randomized controlled trial of 216 participants comparing Constraint Induced Aphasia Therapy and Multi-modality Aphasia Therapy to usual care for people with aphasia 6 months to 15 years following stroke. Primary outcome is aphasia severity immediately following treatment plus secondary outcomes at 3 months post treatment. An economic analysis will occur.

Trial URL:

ANZCTR No: ACTRN126125000618550

www.latrobe.edu.au/compare

www.facebook.com/latrobeaphasia

www.twitter.com/compareaphasia

Last Updated ( Wednesday, 10 January 2018 12:45 )
 
Page 2 of 4


ASTN Latest news

Top Views